During the corresponding time, Adma Biologics Inc saw a revenue deteriorated by -0.3 % year on year, sequentially revenue fell by -18.26 %. While revenue at the Adma Biologics Inc 's corporate clients
Adma Biologics Inc's Comment on Sales, Marketing and Customers
The company operates FDA-approved plasma collection centers, including three centers approved by the Korean Ministry of Food and Drug Safety and ADMA BioCenters, which also holds FDA approval for a Hepatitis B immunization program. Plasma collected is sold to third-party customers in the United States and internationally through supply agreements or on the open market. In 2025, the company divested three plasma collection centers but continues to own and operate seven centers, maintaining long-term plasma supply agreements with the purchaser of the divested centers. Additionally, the company provides contract manufacturing, laboratory contracting, and fill-finish services to certain third-party clients. In 2025, the company acquired real estate in Boca Raton, Florida, to expand production and storage capabilities. The company's product ASCENIV is a plasma-derived intravenous immunoglobulin (IVIG) containing naturally occurring polyclonal antibodies. Customers and markets include ADMA BioCenters.
Adma Biologics Inc’s Comment on Sales, Marketing and Customers
The company operates FDA-approved plasma collection centers, including three centers approved by the Korean Ministry of Food and Drug Safety and ADMA BioCenters, which also holds FDA approval for a Hepatitis B immunization program. Plasma collected is sold to third-party customers in the United States and internationally through supply agreements or on the open market. In 2025, the company divested three plasma collection centers but continues to own and operate seven centers, maintaining long-term plasma supply agreements with the purchaser of the divested centers. Additionally, the company provides contract manufacturing, laboratory contracting, and fill-finish services to certain third-party clients. In 2025, the company acquired real estate in Boca Raton, Florida, to expand production and storage capabilities. The company's product ASCENIV is a plasma-derived intravenous immunoglobulin (IVIG) containing naturally occurring polyclonal antibodies. Customers and markets include ADMA BioCenters.
Sources:
Adma Biologics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adma Biologics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Adma Biologics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100.62 %